Hydrocodone Reclassification Could Benefit Long-Acting Opioids
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s recommendation that combination hydrocodone products be moved to the more restrictive Schedule II will increase the regulatory burdens for physicians and pharmacies while making the already restricted extended-release oxycodone products relatively more appealing.